Joseph Nano Uncategorized

Migraine’s “in‑between” toll: memory and mood problems are common, small study finds

A new study of adults treated for migraine suggests the condition may affect more than just head pain. In a clinic sample of 60 patients, two out of three screened positive for anxiety and/or depression, and nearly 4 in 10 showed signs of cognitive impairment—even between attacks. The chronic‑migraine group was more likely to be taking medicines with known cognitive side effects, and poorer mental quality‑of‑life scores were more common.    

What the researchers did

Neurology researchers assessed people enrolled in a headache program, comparing those with chronic migraine (≥15 headache days/month) to those with episodic migraine. They used standard screening tools: Mini‑Mental State Examination (MMSE) for overall cognition, SF‑36 for quality of life, and the Hospital Anxiety and Depression Scale (HADS) for mood symptoms.    

Key findings

  • Mood symptoms were common. After excluding a few with missing data, 66% had anxiety and/or depression symptoms on HADS. People with mood symptoms tended to be about 5 years older, reported more stress, and had worse overall quality of life (Table 4, p. 8).    
  • Cognition took a hit in many. Among 57 people with MMSE data, 38.6% screened positive for cognitive impairment. Those screening positive were more often from lower socioeconomic strata and had lower memory scores on a detailed recall test (Table 3, p. 8).    
  • Medication matters. Drugs with potential neurocognitive side effects (e.g., tramadol, topiramate, amitriptyline, imipramine) were used by 90% of chronic‑migraine patients vs 60% of episodic‑migraine patients.  
  • Quality of life and timing. People with worse overall quality of life tended to have a shorter duration since migraine diagnosis and more anxiety symptoms (Table 5, p. 8).  
  • A protective signal from social support. Better perceived social support was linked with a lower likelihood of cognitive impairment in adjusted analyses.  

Why this matters

Migraine is often managed around pain days, but these data highlight hidden “between‑attack” burdens—problems with memory/attention, mood, and day‑to‑day functioning—that can sap wellbeing and complicate treatment choices. Recognizing these patterns may help clinicians screen earlier and tailor therapy, including reviewing medicines that can cloud thinking.    

What people with migraine can do

  • Ask for whole‑person screening. If you live with migraine, talk to your clinician about quick screens for mood (HADS) and cognition (e.g., MMSE or more detailed tests) during routine visits—not just during flares.  
  • Review your medication list. Some commonly used pain and preventive drugs can affect attention and memory; ask whether safer alternatives or dose adjustments are possible for you.  
  • Invest in support. Social support correlated with better cognitive outcomes in this study; building a support network (family, friends, peer groups) may help.  
  • Track quality of life, not just pain days. Tools like the SF‑36 help capture how migraine affects your physical, mental, and social health; sharing these scores can guide care.  

Caveats

This was a small, clinic‑based, cross‑sectional study; it can’t prove cause and effect or represent everyone with migraine. Screening tools flag concerns but don’t replace full diagnostic evaluations. Larger, prospective studies are needed.  

Source: López‑Medina DC and colleagues, BMC Neurology (2025). See especially the methods (p. 4), MMSE result summary (p. 5), and Tables 3–5 (p. 8) for details.        

Editor’s note: This article is for information only and is not a substitute for professional medical advice.